--Preclinical data for Cimeio’s CD45 universal heme ADC and shielded HSCs demonstrate effective depletion of an aggressive AML cell line in vivo-- --First data for Cimeio’s CD33 shielded HSCs show ...
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & ...
Because CD45 is found on nearly all blood cells -- and is usually highly expressed on blood cancer cells -- a treatment that wipes out all CD45-bearing cells would leave patients without any blood ...
Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging. This innovative probe targets CD45 ...
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting ...
CD45 + C1q + CCR8+ cells may serve as a biomarker for kidney disease severity and progression risk, reflecting inflammation and fibrosis. Elevated levels of these cells correlate with serum creatinine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results